Edition:
United States

Oragenics Inc (OGEN.A)

OGEN.A on American Stock Exchange

0.40USD
22 Nov 2017
Change (% chg)

$-0.04 (-9.20%)
Prev Close
$0.44
Open
$0.40
Day's High
$0.40
Day's Low
$0.36
Volume
23,210
Avg. Vol
6,726
52-wk High
$1.10
52-wk Low
$0.28

Chart for

About

Oragenics, Inc. develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic... (more)
No analyst recommendations are available for .

Overall

Beta: 1.20
Market Cap(Mil.): $19.69
Shares Outstanding(Mil.): 49.27
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.56 15.47
EPS (TTM): -- -- --
ROI: -- 15.17 11.81
ROE: -- 16.58 15.76

BRIEF-Oragenics doses first patient in phase 2 clinical trial of AG013 for oral mucositis

* Oragenics doses first patient in phase 2 clinical trial of AG013 for oral mucositis

Aug 31 2017

BRIEF-Oragenics announces completion of second closing of $3.0 million preferred stock private placement

* Oragenics announces completion of second closing of $3.0 million preferred stock private placement Source text for Eikon: Further company coverage:

Jul 26 2017

Competitors

Earnings vs. Estimates

No consensus analysis data available.